<DOC>
	<DOCNO>NCT02121639</DOCNO>
	<brief_summary>The aim ProCAID study determine addition AKT inhibitor AZD5363 docetaxel prednisolone ( DP ) prolongs progression free survival ( PFS ) Metastatic castration resistant prostate cancer degree worthy investigation</brief_summary>
	<brief_title>Open Label Phase I/Randomised , Double Blind Phase II Study mCRPC AZD5363 In Combination With DP Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>1 . Histologically cytologically proven mCRPC documented metastasis ( measurable evaluable disease acceptable ) eligible treatment docetaxel chemotherapy 2 . Disease progression since last change therapy define one follow accord Prostate Cancer Working Group ( PCWG2 ) criterion ( J Clin Oncol 2008 ; 26:11481159 ) : i. PSA progression define prostate cancer work group ( 2 ) ( PCWG2 ) criterion ( Scher et al . 2008 J Clin Oncol . 26 ; 1148 ) . This must base series least 3 reading least 7 day apart . The 3rd reading must &gt; = 2ng/ml . In event intermediate read lower previous reading , patient still eligible ( ie . 3 reading need consecutive ) . The first three reading must obtain commence previous systemic therapy , , case androgen receptor antagonist , discontinue . ii . Radiographic progression nodal visceral metastasis define RECIST version 1.1 ( Eur J Cancer 2009 ; 45:228 ) . See Appendix 5 iii . The appearance two new bony metastases 3 . Serum testosterone &lt; 1.7 nmol/L ( ongoing LHRH analogue antagonist therapy permit maintain castrate state ) 4 . Discontinuation prior therapy prostate cancer ≥ 4 week prior commence study treatment ( exception LHRH agonist antagonist require ongoing testosterone suppression ) 5 . No antiandrogen withdrawal response . Withdrawal responses typically occur follow combined androgen blockade ( LHRH analogue/antagonist orchidectomy combine antiandrogen ) initial therapy prolong period , patient respond antiandrogen secondline therapy . Consistent PCWG2 guideline , investigator evaluate patient withdrawal response 6 week confirm disease progression . Investigators need wait ass withdrawal response patient respond , show PSA decline ≤ 3 month , antiandrogen administer secondline later intervention 6 . ECOG performance status 0 1 7 . Hb ≥ 9g/dL ; platelet ≥ 100 x 109/L ; neutrophil ≥ 1.5 x109/L 8 . Bilirubin ≤ ULN ; ALT AST ≤ 1.5 x ULN 9 . Sodium potassium within normal range site 10 . Able swallow study drug ( without crushing/opening case AZD5363 ) 11 . Life expectancy &gt; 3 month 12 . Aged 18 year 13 . Provision write informed consent 1 . Previous treatment cytotoxic chemotherapy ( patient may receive previous ongoing bisphosphonates denosumab ) . There restriction prior use second generation hormonal therapy e.g . abiraterone , enzalutamide 2 . Prior malignancy estimate ≥ 30 % chance relapse within 2 year follow curative treatment 3 . Previously identify brain metastasis , spinal cord compression unless treat full functional recovery 4 . Prior radiotherapy &gt; 30 % bone marrow 5 . Administration investigational agent within 30 day first dose study medication 6 . Type I II diabetes mellitus require either insulin oral hypoglycaemics routine management . Patients type II diabetes mellitus well control dietary measure alone eligible participate . Patients find fast glucose ≥7 mmol/L ( ≥126 mg/dL ) glycosylated haemoglobin &gt; 8 % ( 64 mmol/mol ) screening assess appropriate management accord local policy . Those dietary measure alone provide good diabetic control eligible inclusion 7 . Malabsorption syndrome , previous gastrointestinal surgery , gastrointestinal condition may affect drug absorption 8 . Coronary artery bypass graft , angioplasty , vascular stent , myocardial infarction , angina pectoris congestive heart failure ( NYHA ≥ grade 2 ) within last 6 month 9 . Abnormal echocardiogram ( LVEF &lt; LLN ) 10 . Uncontrolled hypotension ( systolic blood pressure &lt; 90 mmHg and/or diastolic blood pressure &lt; 50 mmHg ) 11 . QTc interval &gt; 480 msec two time point within 24 hour period 12 . Proteinuria ( 3+ dipstick analysis &gt; 500 mg/24 hour ) creatinine &gt; 1.5 x ULN concurrent creatinine clearance &lt; 50 mL/min 13 . Proteinuria ( either 3+ dipstick analysis &gt; 500 mg/24 hour ) creatinine &gt; 1.5 x ULN concurrent creatinine clearance &lt; 50 mL/min ( assess per local practice e.g . Cockcroft Gault estimation ) 14 . Exposure potent inhibitor inducer CYP3A4 CYP2D6 substrates CYP3A4 within 2 week first dose study treatment ( 3 week St John 's Wort ) 15 . Unresolved toxicity ≥ grade 2 ( except alopecia ) previous cancer therapy 16 . Patients partner childbearing potential use highly effective method contraception , unwilling use condom study 30 day last dose study drug 17 . Known hypersensitivity AZD5363 , excipients , drug class 18 . Previous exposure agent follow mechanisms action : inhibition AKT ( e.g. , MK2206 , GDC0068 , GSK2110183 , GSK2141795 ) inhibitor PI3K pharmacology ( e.g. , GDC0941 , XL147 , BKM120 , PX866 , BYL719 , AMG319 , GDC0032 , INK1117 , INK119 ) compound mixed PI3K mammalian target rapamycin ( mTOR ) kinase pharmacology ( e.g. , BEZ235 , GDC0980 , PF04691502 , PF05212384 , GSK2126458 , XL765 ) mTOR kinase inhibitor ( e.g. , AZD8055 , AZD2014 , OSI027 , INK128 ) Note : Do exclude patient previously treat rapalogue ( allosteric inhibitor mTOR ; mTORC1 complex inhibitor ) include temisirolimus ( Torisel ; Pfizer ) , everolimus ( Affinitor ; Novartis ) , ridoforolimus ( Ariad ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Metastatic Castration Resistant Prostate Cancer</keyword>
	<keyword>AZD5363</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Prednisolone</keyword>
</DOC>